Skip to main content
Celon Pharma S.A. logo

Celon Pharma S.A. — Investor Relations & Filings

Ticker · CLN ISIN · PLCLNPH00015 LEI · 259400Q0ERJT0NC5DT24 WAR Manufacturing
Open in API
Filings indexed 709 across all filing types
Latest filing 2024-06-21 Declaration of Voting R…
Country PL Poland
Listing WAR CLN

About Celon Pharma S.A.

https://celonpharma.com/en/

Celon Pharma S.A. is an integrated pharmaceutical company that conducts advanced research and manufactures modern drugs. The company is engaged in the development, production, distribution, and marketing of therapeutic solutions. Its primary focus is on developing treatments for cancers, neurological diseases, diabetes, and other metabolic disorders. As a marketing authorization holder, Celon Pharma manages the full product lifecycle, from scientific research and development to commercialization, aiming to improve patient health and quality of life.

Recent filings

Filing Released Lang Actions
Wykaz akcjonariuszy posiadających co najmniej 5% głosów na Zwyczajnym Walnym Zgromadzeniu Celon Pharma S.A. w dniu 21 czerwca 2024 r. - Content (PL)
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document text explicitly mentions 'Zwyczajnym Walnym Zgromadzeniu Spółki' (Annual General Meeting of the Company) held on June 21, 2024, and lists the shareholders who held at least 5% of the votes and the corresponding number of votes they held at that specific meeting. This content directly relates to the results or details of a shareholder vote at a general meeting. This aligns perfectly with the definition for Declaration of Voting Results & Voting Rights Announcements (DVA). The document is short and reports specific voting outcomes.
2024-06-21 Polish
zal03_Celon_Pharma_Sprawozdanie_Rady_Nadzorczej_za_2023.pdf
Governance Information Classification · 1% confidence The document is the 'Report of the Supervisory Board' (Sprawozdanie Rady Nadzorczej) for Celon Pharma S.A. for the fiscal year 2023. This document is a mandatory corporate governance report required by the Polish Commercial Companies Code (KSH) and the Warsaw Stock Exchange (GPW) Best Practices. It details the board's oversight activities, evaluation of financial statements, and internal control assessments. It is a governance-related report rather than a financial statement itself, an earnings release, or a simple announcement. Therefore, it falls under the Governance Information category. FY 2023
2024-06-21 Polish
zal01_Sprawozdanie_o_wynagrodzeniach_Czlonkow_Zarzadu_i_RN_Celon_Pharma_SA_za_2023.pdf
Remuneration Information Classification · 1% confidence The document is titled "SPRAWOZDANIE O WYNAGRODZENIACH CZŁONKÓW ZARZĄDU I RADY NADZORCZEJ..." which translates to "REPORT ON REMUNERATION OF MANAGEMENT BOARD AND SUPERVISORY BOARD MEMBERS...". It details the compensation structure, amounts paid to board members and supervisory board members for the fiscal year 2023, and compares these figures over the last five years (2019-2023). This content directly aligns with the definition of a Remuneration Information report, which corresponds to the DEF 14A code in the provided schema, even though the document is in Polish and references Polish law (Art. 90g of the Act on Public Offering). The document is comprehensive and appears to be the full report itself, not just an announcement of its publication.
2024-06-21 Polish
zal02_Uchwaly_ZWZ_Celon_Pharma_21.06.2024.pdf
AGM Information Classification · 1% confidence The document text is titled "UCHWAŁY ZWYCZAJNEGO WALNEGO ZGROMADZENIA CELON PHARMA S.A. Z DNIA 21 CZERWCA 2024 ROKU" (Resolutions of the Annual General Meeting of Celon Pharma S.A. dated June 21, 2024). It details multiple resolutions passed during this meeting, including the election of the Chairman, approval of the agenda, approval of the Management Board Report for 2023, approval of the Financial Statements for 2023, decisions on loss coverage and dividend payment, and granting of discharge (absolutorium) to management board members for their duties in 2023. These documents explicitly record the outcomes and resolutions of a General Meeting, which aligns perfectly with the definition of AGM Information (AGM-R). While it contains elements related to remuneration (absolutorium votes) and annual reports (approving 2023 financials), the primary nature and structure are the formal record of the Annual General Meeting proceedings and results.
2024-06-21 Polish
Uchwały podjęte przez Zwyczajne Walne Zgromadzenie Celon Pharma S.A. w dniu 21 czerwca 2024 r. - Content (PL)
AGM Information Classification · 1% confidence The document text is very short (929 characters) and explicitly states that the Management Board ('Zarząd') is enclosing ('przekazuje w załączeniu') the content of the resolutions ('treść uchwał') adopted by the Ordinary General Meeting ('Zwyczajne Walne Zgromadzenie') held on June 21, 2024. It also mentions attached reports like the Supervisory Board Report and the Remuneration Report, which were approved during the meeting. Because the document is an announcement *about* resolutions and attached materials from the AGM, rather than the full AGM presentation or the full text of the resolutions themselves, it fits best as an announcement related to the AGM. However, since the core content is the resolutions and associated reports from the AGM, and given the options, AGM-R (AGM Information) is the most appropriate classification for the material *resulting* from the meeting, especially since DVA (Declaration of Voting Results) is usually just the results, and this includes the resolutions themselves. Given the context of providing the resolutions and related reports from the AGM, AGM-R is selected. The 'Menu vs Meal' rule suggests RPA/RNS if it were just announcing the publication, but here it seems to be the primary communication of the AGM outcomes/attachments.
2024-06-21 Polish
Uchwała Zwyczajnego Walnego Zgromadzenia Spółki w sprawie w sprawie pokrycia straty oraz wypłaty dywidendy za rok obrotowy 2023 - Content (PL)
AGM Information Classification · 1% confidence The document text explicitly states that the Annual General Meeting (Zwyczajne Walne Zgromadzenie) held on June 21, 2024, passed a resolution regarding the coverage of the net loss and the payment of a dividend for the fiscal year 2023. The key elements are the resolution on dividend payment (0.08 PLN per share), the record date (June 28, 2024), and the payment date (July 4, 2024). This content directly corresponds to the definition of 'Notice of Dividend Amount' (DIV). Although it originates from an AGM, the core subject matter is the dividend declaration, making DIV the most specific classification.
2024-06-21 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.